leteprinim
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 29, 1999 (NCT00000180)
Timeline
Indications
Mechanism of action
- Beta-nerve growth factorMODULATOR
NGF modulator
Chemistry & pharmacology
Loading structure…
SMILES
O=C(CCn1cnc2c(=O)[nH]cnc21)Nc1ccc(C(=O)O)cc1- Mol. weight
- 327.3 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2104345 ↗
- ChEMBLCHEMBL2146108 ↗
Also known as
- 4-((3-(1,6-dihyro-6-oxo-9h-purin-9-yl)-1-oxopropyl)amino)benzoic acid
- ait 082
- ait-082
- ait-082
- ait-082
- ait-082
- leteprinim
- leteprinim
- leteprinim
- leteprinim
- leteprinim potassium
- leteprinim potassium
- leteprinim potassium
- leteprinim potassium
- leteprinim potassium
- leteprinim potassium
- neotrofin
- neotrofin
- neotrofin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00041795 | Phase 2 | Jan 1, 2002 | Spectrum Pharmaceuticals |
| NCT00000180 | Phase 1 | Oct 29, 1999 | National Institute on Aging (NIA), University of California, San Diego |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute on Aging (NIA) | Government | 1 | 1 | 1 | 1999 |
| Spectrum Pharmaceuticals | For profit | 1 | 1 | 1 | 2002 |
| University of California, San Diego | Academic/Hospital | 1 | 0 | 1 | 1999 |
3 organizations
Page 1 / 1